The conversation is about the safety of Breezula compared to RU58841 for hair loss treatment. The user believes Breezula is safer but less effective than RU58841.
Dutasteride is more effective than finasteride for hair loss, especially at the crown and midscalp, but both have similar side-effect profiles with low incidence of sexual adverse events. Improvement is measured visually, and significant results may take over 12 months to appear.
Clascoterone (CB) shows an excellent safetyprofile with no serious side effects, but its effectiveness may decline after six months, making it more suitable as an adjunct treatment with finasteride and minoxidil rather than a standalone solution. Some argue it could be better than finasteride due to its protection against testosterone, but its long-term efficacy remains debated.
Dutasteride is more effective than Finasteride for hair loss, with similar safetyprofiles. Individual responses vary, and factors like Minoxidil use and age differences may influence results.
Topical finasteride may have higher systemic absorption and lower efficacy when using a Propylene Glycol/Ethanol formulation compared to the hydroxypropyl chitosan (HPCH) formulation. The safetyprofile of topical finasteride relies heavily on the HPCH formulation, and using standard solutions might lead to different pharmacokinetics.
The user stopped using finasteride due to side effects and is considering Fluridil (Eucapil) as an alternative for hair loss treatment. They are exploring other options like RU58841 and are interested in the experiences of others with Fluridil, noting its good safetyprofile despite the cost.
AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safetyprofile and good local tolerability in early trials.
The user is considering adding Pyrilutamide or Alfatradiol as a topical treatment for hair loss after oral Finasteride and Dutasteride became less effective. Other users suggest Pyrilutamide for its safetyprofile, while one user shares positive experiences with RU58841 for reducing scalp itch and improving hairline.
RU58841 is a strong non-steroidal antiandrogen for hair loss but may cause cardiovascular issues in some users. Alternatives like Pyrilutamide and Breezula are suggested due to better safetyprofiles and lower systemic risks.
RU58841 users report mixed results, with some experiencing no benefits and others noting regrowth but potential side effects. Many prefer finasteride and minoxidil due to better-studied safetyprofiles.
User shares 3.5-month hair transformation using 0.5 mg Dutasteride daily and Minoxidil 2x daily. Others express amazement and discuss safetyprofiles of treatments.
The conversation discusses anticipation for CB-03-01, a potential new hair loss treatment that may be more effective and have a cleaner safetyprofile than finasteride. Users are hopeful but cautious, discussing current treatments like minoxidil, nizoral, and dermarolling, and the possibility of combining them with CB-03-01 for better results.
Hair loss treatments discussed include minoxidil, finasteride, dutasteride RU, derma rolling, pyrilutamide, cosmeRNA, hair systems, and essential oils. The user seeks information on additional treatments, safetyprofiles, and alternative options for androgenetic alopecia.
The conversation discusses the safety study of PP405, emphasizing that early trials focus on safety rather than efficacy, and that any efficacy data from such a short study should be viewed skeptically. It also highlights that the information released is primarily for securing funding, and that meaningful efficacy results are expected in later phases.
Hair loss treatments, specifically the use of oral minoxidil in combination with micro-needling. Oral minoxidil has been found to improve hair density in 90% of patients with a low side effect profile, but using 5mg per day can result in higher side effects including hypertrichosis and edema. Other treatments mentioned include finasteride and RU58841.
TDM-105795 showed better efficacy and safety in trials for hair loss, with a higher hair count improvement compared to GT20029 and HMI 115, but it's not as widely discussed. The user is questioning why this is the case.
The conversation is about the potential availability of GT20029 on the black market and whether users would try it. Participants advise waiting for phase 3 trial results to ensure safety and efficacy.
The discussion is about a hair loss drug called pyrilutamide. Users discuss its efficacy, safety, and expected market release around 2025-2026, with some expressing concerns about the authenticity of current market offerings.
The conversation discusses the safety and use of ketoconazole shampoo for hair loss, with mentions of zinc pyrithione and selenium sulfide. Users debate the safety of these ingredients, particularly zinc pyrithione, and share opinions on regulatory differences between Europe and the US.
The post discusses the user's experience with hair loss treatment RU58841, which was tested for quality and found to be 96+% pure. The conversation includes various responses, with some users questioning the safety of the product and others expressing satisfaction with the test results.
The conversation is about the safety and effects of using pyrilutamide for hair loss. One person reported severe negative effects, another experienced minor side effects without much benefit for hair, and a third found the anecdote helpful in making a decision.
RU58841 lacks FDA approval due to financial and safety concerns, including potential cardiological side effects. The company abandoned further research, and users report adverse effects like heart palpitations and gynecomastia.
RU58841 powder is being discussed as a hair loss treatment, with concerns about its legitimacy and safety when purchased from Amazon. The conversation also mentions Minoxidil as a comparison in terms of price.
Way-316606 is considered a potential hair loss treatment but is avoided due to safety concerns and lack of research. Minoxidil and Finasteride are preferred as established treatments.
RU58841 is discussed as a topical anti-androgen for hair loss, but its effectiveness and safety are not well-documented, leading to mixed opinions and experiences among users. Some combine it with finasteride, but concerns about side effects and lack of FDA approval limit its popularity.
PP405 is anticipated as a future treatment for dormant hair follicles, but its effectiveness and safety are uncertain. Current treatments include oral minoxidil and microneedling, with some avoiding finasteride due to side effects.
The user stopped using finasteride due to side effects and switched to RU58841, which seems to be working for hair regrowth. They are considering RU58841 and minoxidil as long-term treatments, while others discuss the safety and effectiveness of these options.
Clascoterone 5% topical solution shows promise for treating male-pattern hair loss by blocking DHT at the follicle without systemic absorption, potentially offering fewer side effects than oral treatments like finasteride. While results are promising, long-term safety and effectiveness need further study, and it may serve as a starting point for developing more effective treatments.
PP405 is discussed as a potential hair loss treatment, but its effectiveness and safety are uncertain. Some users express skepticism, while others are hopeful, comparing it to existing treatments like Minoxidil and Finasteride.
A user discusses a dermatologist-prescribed topical solution for hair loss containing 7% Minoxidil, 0.0125% Tretinoin, and 0.1% Dutasteride, questioning its safety. Responses suggest the concentration is generally safe, though there is skepticism about daily use at high concentrations, and similar products like HairStim and Happy Head are mentioned.